Journal of palliative care
Impact of Hydrocodone Rescheduling on Pharmaceutical Pain Management in End-of-Life Lung Cancer Patients.
Chan Shen, Mohammad Ikram, Shouhao Zhou, Roger Klein, James Douglas Thornton, Douglas Leslie
Published: 202510.1177/08258597251398132
Abstract
ObjectiveLung cancer is the leading cause of cancer mortality in the USA, and terminal patients endure severe pain. In October 2014, hydrocodone was rescheduled from Schedule III to Schedule II to curb misuse, yet its specific impact on end-of-life l…
Preview only. Read the full abstract at the source